Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1998 4
1999 2
2000 3
2001 6
2003 1
2004 2
2018 1
2019 1
2020 1
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, Karlsson S, Rummakko P, Simola O, Wohlfahrt G, Hakulinen P, Vuorela A, Joensuu H, Utriainen T, Fizazi K, Oksala R. Karimaa M, et al. Among authors: taavitsainen p. Mol Cancer Ther. 2022 Dec 2;21(12):1765-1776. doi: 10.1158/1535-7163.MCT-22-0115. Mol Cancer Ther. 2022. PMID: 36129801
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Pelkonen O, et al. Among authors: taavitsainen p. Xenobiotica. 1998 Dec;28(12):1203-53. doi: 10.1080/004982598238886. Xenobiotica. 1998. PMID: 9890159 Review. No abstract available.
CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L. Scheinin H, et al. Among authors: taavitsainen p. Clin Pharmacol Ther. 1998 Oct;64(4):402-11. doi: 10.1016/S0009-9236(98)90071-6. Clin Pharmacol Ther. 1998. PMID: 9797797 Clinical Trial.
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R, Moilanen A, Riikonen R, Rummakko P, Karjalainen A, Passiniemi M, Wohlfahrt G, Taavitsainen P, Malmström C, Ramela M, Metsänkylä HM, Huhtaniemi R, Kallio PJ, Mustonen MV. Oksala R, et al. Among authors: taavitsainen p. J Steroid Biochem Mol Biol. 2019 Sep;192:105115. doi: 10.1016/j.jsbmb.2018.02.004. Epub 2018 Feb 10. J Steroid Biochem Mol Biol. 2019. PMID: 29438723 Free article.
25 results